Get the Stockscreener App
2.12
2.30%
-0.05
After Hours:
2.03
-0.09
-4.25%
Organovo Holdings Inc stock is traded at $2.12, with a volume of 63,534.
It is down -2.30% in the last 24 hours and down -70.90% over the past month.
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.
See More
Previous Close:
$2.17
Open:
$2.04
24h Volume:
63,534
Relative Volume:
0.10
Market Cap:
$3.82M
Revenue:
-
Net Income/Loss:
$-19.09M
P/E Ratio:
-0.977
EPS:
-2.17
Net Cash Flow:
$-16.92M
1W Performance:
-12.03%
1M Performance:
-70.90%
6M Performance:
-62.09%
1Y Performance:
-83.17%
1-Day Range:
$1.96
$2.1375
1-Week Range:
$1.96
$2.44
52-Week Range:
$1.96
$21.96
Organovo Holdings Inc Stock (ONVO) Company Profile
Name
Organovo Holdings Inc
Sector
Industry
Phone
858-224-1000
Address
11555 SORRENTO VALLEY ROAD, SAN DIEGO, CA
Compare ONVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONVO
Organovo Holdings Inc
|
2.12 | 3.82M | 0 | -19.09M | -16.92M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Organovo Holdings Inc Stock (ONVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-18 | Initiated | H.C. Wainwright | Buy |
| Nov-10-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-25-17 | Initiated | Raymond James | Outperform |
| Aug-11-15 | Downgrade | Cantor Fitzgerald | Buy → Hold |
| Jun-29-15 | Initiated | Jefferies | Buy |
| Jun-29-15 | Initiated | Piper Jaffray | Overweight |
View All
Organovo Holdings Inc Stock (ONVO) Latest News
Organovo (NASDAQ:ONVO) Earns Sell Rating from Analysts at StockNews.com - Defense World
Organ On A Chip Market Generated Opportunities, Future Scope - openPR.com
Organovo (ONVO) Anticipates $5M Cash Influx as Nasdaq Compliance Continues - GuruFocus
Organovo reports $11.3M cash balance in FY24 - MSN
Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements - The Manila Times
Organovo Holdings Expects to Meet Nasdaq Listing Requirements - TipRanks
Organovo expects to maintain Nasdaq listing with stable stock price By Investing.com - Investing.com Australia
Organovo expects to maintain Nasdaq listing with stable stock price - Investing.com
Organovo's Financial Update: $11.3M Cash Reserve Plus $55M Potential Milestone Payments - Stock Titan
Organovo stock plunges to 52-week low of $2.13 amid steep decline - Investing.com Canada
ONVO Stock Quote Price and Forecast - CNN
Organovo Holdings (ONVO) Sells FXR Program to Lilly (LLY), Secures Financial Future - GuruFocus
Organovo sells FXR Program, anticipates reduced costs By Investing.com - Investing.com South Africa
Organovo gets upfront payments following sale of its FXR Program to Lilly - Seeking Alpha
Organovo Provides Business Update - Quantisnow
Organovo sells FXR Program, anticipates reduced costs - Investing.com India
Organovo Holdings Completes Sale of FXR Program to Lilly - TipRanks
StockNews.com Initiates Coverage on Organovo (NASDAQ:ONVO) - Defense World
Organovo Holdings Inc Receives Upfront Payments From FXR Program Sale To Lilly - MarketScreener
Latest: Organovo Secures Future Through 2026 Following Major Lilly Partnership Deal - Stock Titan
Organovo Holdings Completes FXR Program Sale to Eli Lilly - TipRanks
Organovo Announces Close Of Sale Of FXR Program To Eli Lilly And Company - Marketscreener.com
Eli Lilly Wraps Up Acquisition of Organovo's FXR Program - Marketscreener.com
Organovo Completes Sale of FXR Program to Eli Lilly - Marketscreener.com
Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company - The Manila Times
Organovo Announces Close Of The Sale Of FXR Program To Eli Lilly And Company - menafn
Major Deal: Eli Lilly Acquires Organovo's FXR Program in Strategic Asset Purchase - Stock Titan
Healthcare 3D Printing Market Demand, Growth and Future Scope - openPR.com
3D Printing in Regenerative Medicine Market Generated - openPR.com
Organovo stock hits 52-week high at $3.67 amid market fluctuations - Investing.com Australia
Organovo announces 1-for-12 reverse stock split - Investing.com India
Organovo announces 1-for-12 reverse stock split By Investing.com - Investing.com Australia
Organovo Announces 1-for-12 Reverse Stock Split To Maintain Nasdaq Compliance - Nasdaq
Dow Surges Over 200 Points; US Crude Oil Inventories Increase More than Expected - Benzinga
Nasdaq Gains Over 1%; Williams-Sonoma Shares Plunge After Q4 Results - Benzinga
Organovo announces reverse stock split; shares fall - MSN
Organovo Announces 1-for-12 Reverse Stock Split - TipRanks
Organovo Announces Reverse Stock Split - The Manila Times
Organovo Holdings, Inc. Announces 1-for-12 Reverse Stock Split Effective March 20, 2025 - Nasdaq
Organovo's Major Stock Restructuring: 1:12 Reverse Split Coming March 20 - StockTitan
Organovo (NASDAQ:ONVO) Now Covered by StockNews.com - Defense World
Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors - The Manila Times
Matinas BioPharma Lands Organovo Chairman, Pharma Veteran in Strategic Board Revamp - StockTitan
Organovo Holdings, Inc. to Host Earnings Call - ACCESS Newswire
Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises - The Manila Times
Can Organovo's $2.3M Capital Raise Fuel Its IBD Treatment Development? - StockTitan
Organovo Holdings Inc: Is ONVO Stock Worth Buying? - Stocks Register
Organovo Holdings Inc Stock (ONVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):